DSIP (Delta Sleep-Inducing Peptide) Complete Guide: Benefits, Dosing, Side Effects & Research

Introduction

Delta sleep-inducing peptide (DSIP) is a nine-amino-acid neuropeptide first isolated by Monnier and Schoenenberger in 1977 from rabbit cerebral venous blood during electrical stimulation of the thalamus. The team published the finding in Experientia, naming it for its ability to induce delta-wave EEG activity in recipient rabbits. Almost fifty years later, the human evidence remains thin.

DSIP shows up in online peptide forums as a sleep aid, a stress modulator, an opioid-withdrawal helper, and a chronic-pain tool. The actual peer-reviewed human data behind those claims comes from a handful of small studies, most published before 1990. No FDA-approved indication exists. No phase 3 trials are running. That gap between marketing claims and clinical evidence is what this guide is about.

This page covers what DSIP is, how it was studied, what dosing protocols have appeared in published research, the safety signals that exist, and where the science actually stands in 2026. If you’re considering DSIP, you should know the evidence base before you spend money.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is DSIP and Where Did It Come From?

DSIP is a small linear peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Monnier and Schoenenberger isolated it from the cerebral venous blood of rabbits whose intralaminar thalamus had been stimulated to produce sleep-like states. They reported the work in a 1977 paper in Experientia and a 1984 review in Neuroscience and Biobehavioral Reviews.

Quick Answer: DSIP is a 9-amino-acid peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated by Schoenenberger and Monnier in 1977

The original idea was that this peptide carried a humoral sleep signal between brain regions. When researchers infused it into other animals, recipients showed increased delta-frequency EEG activity, the slow waves associated with deep non-REM sleep. That finding launched the peptide’s career.

DSIP is endogenous. It’s been detected in human plasma, cerebrospinal fluid, milk, and various tissues, though concentrations are low and assay methods have been inconsistent. No specific high-affinity receptor has been cloned, which is one reason the mechanism stays murky.

Does DSIP Actually Improve Sleep in Humans?

The evidence is limited and dated. The most cited human trial is Schneider-Helmert’s 1986 study in Pharmacopsychiatry, which tested DSIP in 16 patients with chronic insomnia. Patients received 25 nmol/kg intravenously and showed reduced sleep latency, fewer awakenings, and improvements that persisted for several weeks after dosing stopped.

A 1989 follow-up by the same group in Pharmacology Biochemistry and Behavior reported similar findings in a slightly larger cohort. Other small studies from the 1980s by Schoenenberger, Kastin, and others reported variable effects, with some showing changes in REM proportions and others showing no change in objective sleep architecture.

What’s missing is what you’d want for a modern sleep drug: a multi-center randomized placebo-controlled trial with polysomnography, validated subjective sleep scales, and active comparators like zolpidem or trazodone. That trial has not been done. The European Medicines Agency and FDA have no approval files on DSIP.

How Is DSIP Supposed to Work Mechanistically?

The honest answer is that nobody knows. DSIP does not bind any well-characterized receptor. It crosses the blood-brain barrier in small amounts, has a plasma half-life under 15 minutes, and produces effects that often outlast its measurable presence in circulation.

Proposed mechanisms in the literature include modulation of GABAergic tone, effects on serotonin and norepinephrine release, interaction with opioid systems (some studies showed DSIP attenuated morphine tolerance), and downstream effects on circadian gene expression. Graf and colleagues in a 1986 Peptides paper showed DSIP altered EEG patterns even after intracerebroventricular injection of very small amounts, suggesting a central rather than peripheral site of action.

The lack of a defined receptor is a real problem for drug development. Without that target, you can’t run structure-activity relationship studies, you can’t develop selective agonists, and you can’t reliably screen for off-target effects.

What Dosing Protocols Appear in the Literature?

Published human studies have used intravenous infusions in the range of 25 to 60 nmol per kilogram body weight. For an 80 kg adult, 25 nmol/kg works out to roughly 2 micromoles, or about 1.9 mg of DSIP given the molecular weight of around 849 daltons.

Some studies used intranasal delivery. Larbig and colleagues in a 1984 European Journal of Pharmacology paper tested intranasal DSIP at doses around 0.1 mg per dose for chronic pain and reported some analgesic effect. Subcutaneous dosing has not been systematically studied in published peer-reviewed trials.

Compounding pharmacies and gray-market peptide vendors typically sell DSIP for subcutaneous injection at 100 to 500 micrograms before bed. These doses come from forum protocols, not from controlled trials. There is no FDA-cleared dosing guidance.

Is DSIP Safe? What Side Effects Have Been Reported?

Reported acute side effects in the small published trials are minimal. Schneider-Helmert’s patients reported mild headache, transient nausea, and occasional dizziness. No serious adverse events were reported in the published literature, but the total exposed population across all published human studies is probably under 200 people.

That is far too small to establish safety. Rare but serious events like anaphylaxis, hepatotoxicity, or neurological effects would not show up in a sample this size. Long-term effects on hormonal axes, immune function, or chronic disease risk are entirely unstudied.

A 2014 review in Pharmacology Biochemistry and Behavior by Bondarenko and colleagues noted that DSIP has been studied in Russian and Eastern European research for decades, with claimed effects on stress resistance and longevity. Those studies generally don’t meet Western standards for trial design and shouldn’t be treated as definitive safety data.

How Does DSIP Compare to Approved Insomnia Medications?

DSIP has no head-to-head comparison data against zolpidem, eszopiclone, suvorexant, lemborexant, trazodone, or any other approved hypnotic. Modern orexin antagonists like Belsomra and Quviviq have been tested in trials of thousands of patients with polysomnography endpoints. DSIP has not.

Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line treatment recommendation from the American Academy of Sleep Medicine, with effect sizes comparable to or better than hypnotic drugs and durable benefits. Anyone considering DSIP for sleep should know CBT-I exists and is covered by most insurance plans.

For comparison, melatonin, an over-the-counter peptide-derived hormone, has dozens of placebo-controlled trials and clear dosing guidance. DSIP does not.

Key Takeaway: Schneider-Helmert’s 1986 study in chronic insomniacs used 25 nmol/kg IV and showed modest sleep improvements

What About DSIP for Stress, Pain, and Opioid Withdrawal?

Small studies in the 1980s and 1990s reported DSIP effects on stress markers, chronic pain perception, and symptoms of opioid withdrawal. Dick and colleagues in a 1983 European Neurology paper reported DSIP reduced opioid withdrawal severity in a small sample. Iyer and McCann in 1987 reported DSIP altered hypothalamic-pituitary-adrenal axis responses.

None of these signals have been replicated in modern trials. The opioid epidemic has driven massive investment in addiction medicine research, including peptide approaches, and DSIP has not surfaced as a serious candidate. That absence is itself informative.

For chronic pain, the modern evidence base centers on SNRIs like duloxetine, gabapentinoids, and non-pharmacologic approaches like physical therapy and acceptance and commitment therapy. DSIP isn’t in the conversation.

Where Can You Legally Get DSIP and What’s the Quality Risk?

DSIP is not FDA-approved and is not available as a prescription medication in the United States. It’s sold by research chemical suppliers and some compounding pharmacies, generally labeled “for research use only” or as a custom compound.

The quality risk is significant. Independent third-party testing of peptide products sold online has repeatedly found mislabeled potency, contamination with endotoxins from bacterial production, and presence of related but distinct peptide sequences. A 2020 analysis of growth hormone secretagogue products published in Drug Testing and Analysis found wide variability between labeled and actual content.

If you’re considering peptide therapy of any kind, working with a licensed prescriber and a state-board-registered compounding pharmacy is the minimum safety floor. TrimRx focuses on FDA-approved active ingredients in compounded GLP-1 medications, where the regulatory framework is far clearer than it is for experimental peptides like DSIP.

How Does DSIP Fit Into a Modern Sleep Workup?

If you have chronic insomnia, the evidence-based workup is well established. Screen for sleep apnea, especially if you snore, are overweight, or wake unrefreshed. Treat any apnea with CPAP or oral appliance. Screen for restless legs syndrome and treat with iron repletion or dopamine agonists if appropriate. Address shift work or circadian misalignment. Try CBT-I.

Only after those steps does pharmacotherapy enter the picture, and even then, approved drugs with safety data come first. DSIP doesn’t have a place in any current clinical guideline for insomnia from the American Academy of Sleep Medicine, the European Sleep Research Society, or any other major body.

That doesn’t mean DSIP is worthless. It means the evidence isn’t there to recommend it, and anyone selling it for sleep is getting ahead of the data.

What Would a Real DSIP Clinical Program Look Like?

A serious development program would start with phase 1 dose-finding in healthy volunteers, with full pharmacokinetics, polysomnography, and safety monitoring. Phase 2 would compare DSIP against placebo in 100 to 200 patients with primary insomnia, using validated endpoints like the Insomnia Severity Index and objective sleep parameters. Phase 3 would scale that to multi-center trials with active comparators.

That program would cost tens of millions of dollars and take five to seven years. No pharmaceutical company has announced such a program for DSIP. The patent situation, the lack of a clear receptor target, and the existence of approved alternatives all work against commercial development.

In the meantime, the peptide sits in a regulatory limbo: real enough to have a sequence and some published data, not real enough to be a medicine.

How Does DSIP Relate to Weight Loss and Metabolic Health?

DSIP is not a weight loss peptide. No published trials have tested DSIP for weight loss, appetite, glucose control, or any metabolic endpoint. The peptide gets discussed in wellness contexts alongside GLP-1 agonists, growth hormone secretagogues, and other compounds, but the mechanistic and clinical evidence base is entirely separate.

If your goal is metabolic health and weight loss, the evidence-based path runs through GLP-1 receptor agonists like semaglutide and dual GIP/GLP-1 agonists like tirzepatide. The STEP 1 trial (Wilding et al. 2021 NEJM) showed 14.9% weight loss with semaglutide at 68 weeks. The SURMOUNT-1 trial (Jastreboff et al. 2022 NEJM) showed 20.9% weight loss with tirzepatide at 72 weeks. Those are the numbers that drove FDA approval.

TrimRx offers a free assessment quiz and personalized treatment plans for compounded semaglutide and tirzepatide, where the evidence base is substantial. Sleep quality often improves naturally with weight loss in patients with obesity-related sleep apnea, and the SURMOUNT-OSA trial showed direct benefit of tirzepatide on sleep apnea severity.

Bottom line: The peptide has a short plasma half-life of around 7 to 15 minutes, raising mechanism questions

FAQ

Is DSIP Legal to Buy in the United States?

DSIP is not a controlled substance under the Controlled Substances Act, but it is also not FDA-approved for any human use. Vendors typically sell it labeled “for research use only,” which is a legal gray zone. Importing or possessing it for personal use exists in a regulatory ambiguity that is not the same as approval.

How Long Does DSIP Stay in Your System?

The plasma half-life is short, roughly 7 to 15 minutes based on early human pharmacokinetic studies. The peptide is broken down by peptidases in blood and tissues. Effects on sleep architecture in some studies persisted for days to weeks after dosing, which doesn’t match the pharmacokinetics and suggests downstream mechanisms that aren’t fully understood.

Can You Take DSIP Orally?

Oral DSIP has very poor bioavailability because gastric and intestinal peptidases degrade the molecule rapidly. Published studies have used intravenous, intranasal, or, more recently in gray-market protocols, subcutaneous routes. Sublingual DSIP products exist commercially but have no published pharmacokinetic data supporting that route.

Does DSIP Cause Tolerance or Withdrawal?

There is no published evidence of tolerance or physical dependence with DSIP. The sample sizes in human trials are too small to detect this reliably, and chronic dosing has not been systematically studied. Absence of evidence is not evidence of absence.

Is DSIP the Same as Melatonin or 5-HTP?

No. DSIP is a peptide, melatonin is an indoleamine hormone, and 5-HTP is an amino acid serotonin precursor. They are chemically distinct, have different mechanisms, and have very different evidence bases. Melatonin and 5-HTP have far more published clinical data than DSIP.

Will DSIP Show up on a Drug Test?

Standard drug screens do not test for DSIP. The peptide is not on the World Anti-Doping Agency prohibited list as of 2026. Athletes considering DSIP should check current WADA guidance directly, as peptide regulations change frequently.

What Does Compounded DSIP Cost?

Pricing varies widely by source. Research-grade peptide vendors typically sell 5 to 10 mg vials for 30 to 60 dollars. Compounding pharmacies that produce DSIP under physician prescription charge more, often 80 to 200 dollars per month at typical dosing. Quality and regulatory oversight vary dramatically between sources, which is the bigger issue than the price.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.